Published in JAMA, well done study in Denmark shows no significant difference in hospital rate contacts for 29 adverse events during 28 day period after MRNA Covid Vax injection.

Results

The cohort totaled 1 585 883 individuals (mean [SD] age, 66.8 [14.5] years; 862 585 female [54.4%]), of whom 1 012 400 individuals (mean [SD] age, 73.5 [10.3] years) received updated mRNA COVID-19 vaccines containing the JN.1 lineage vaccine during follow-up (Table). No statistically significant increases in the rate of hospital contacts for any of 29 adverse events were observed during the 28-day risk period after receipt of a JN.1-containing mRNA vaccine compared with reference period rates (Figure). For example, the incidence rate ratio was 0.84 (95% CI, 0.76-0.94) for ischemic cardiac events, 0.92 (95% CI, 0.76-1.13) for intracranial bleeding, and 1.12 (95% CI, 0.41-3.10) for myocarditis.

https://jamanetwork.com/journals/jamanetworkopen/f...